Oncopharmpod
Updates in Oncology Pharmacy: Adjuvant pertuzumab & nilotinib discontinuation (CML)
- Author: Vários
- Narrator: Vários
- Publisher: Podcast
- Duration: 0:20:20
- More information
Informações:
Synopsis
Review of recent FDA action re: oncology pharmacy including review of the APHINITIY trial and pertuzumab's subsequent approval in the adjuvant setting. Also, the nilotinib label change allowing for discontinuation in CML patients is discussed.
